Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: A 2-year follow-up study

Diabetic Medicine

Volumn 24, Issue 11, 2007, Pages 1254-1260

  Shargorodsky, M ^a   Michaelova, K ^a   Boaz, M ^a,b   Gavish, D ^a   Zimlichman, R ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Arterial elasticity; Arterial pulse wave contour analysis; Diabetes mellitus; Metabolic parameters; Thiazolidinediones

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; FIBRINOGEN; HEMOGLOBIN A1C; INSULIN; ROSIGLITAZONE;

ABDOMINAL PAIN; ADULT; ARTERY; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ELASTICITY; FEMALE; FOLLOW UP; FOOT EDEMA; GLUCOSE HOMEOSTASIS; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMONIA; PROSPECTIVE STUDY; PULSE WAVE; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ARTERIES; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; ELASTICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TIME; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 35448939327     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02231.x     Document Type: Article

References (23)

1. Diep QN, El Mabrouk M, Cohn GS, Endemann D, Amiri F, Virdis A et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 2002 105 : 2296 2302.
2. Shargorodsky M, Wainstein G, Gavish D, Leibovitz E, Matas Z, Zimlichman R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003 16 : 617 622.
3. Saton N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H et al. Anti-atherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its anti-diabetic effect. Diabetes Care 2003 26 : 2493 2499.
4. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Kkoshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998 83 : 1818 1820.
5. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001 86 : 3452 3456.
6. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turmer RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 419.
7. Shargorodsky M, Leibovitz E, Lubimov L, Gavish D, Zimlichman R. Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential arterial hypertension : Am J Hypertens 2002 15 : 1087 1091.
8. Leibovitz E, Hazanov N, Zimlichman R, Shargorodsky M, Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001 14 : 1096 1098.
9. McVeigh GE, Burns DE, Finkelstein SM, McDonald KM, Mock JE, Feske W et al. Reduced vascular compliance as a marker for essential hypertension. Am J Hypertens 1991 4 : 245 257.
10. Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. Am J Hypertens 1999 17 : S41 S42.
11. Cohn JN, Finkelstein S, McVeigh G, Morgan D, LeMay I, Robinson J et al. Non-invasive pulse-wave analysis for the detection of arterial vascular disease. Hypertension 1995 26 : 503 508.
12. Zimlichman R, Shargorodsky M, Boaz M, Duprez D, Rahn KH, Rizzoni D et al. Determination of arterial compliance using blood pressure waveform analysis with the CR-2000 system. Am J Hypertens 2005 18 : 65 71.
13. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentration are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995 91 : 1432 1443.
14. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005 25 : 932 943.
15. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002 106 : 2085 2090.
16. Giannattasio C, Mancia G. Arterial distensibility in humans. Modulating mechanisms, alterations in diseases and effects of treatment. J Hypertens 2002 20 : 1889 1899.
17. Langenfeld MR, Frost T, Hohberg C, Kann P, Lubben G, Konrad T et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Circulation 2005 111 : 2525 2531.
18. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004 24 : 930 934.
19. Igarashi M, Hirata A, Yamaguchi H, Tsuchiya H, Ohnuma H, Tominaga M et al. Characterization of an inhibitory effect of pioglitazoneon balloon-injured vascular smooth muscle cell growth. Metabolism 2001 50 : 955 962.
20. McVeigh GE, Allen PB, Morgan DR, Hanrathy CG, Silke B. Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. Clin Sci 2001 100 : 387 393.
21. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004 89 : 4312 1319.
22. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E et al. Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001 24 : 710 719.
23. Mayerson AB, Hundal S, Dufour S, Lebon V, Befroy D, Cline GW et al. The effect of rosiglitazone on insulin sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002 51 : 797 802.